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Objectives: To assess the cost-effectiveness of simeprevir (SMV) plus peginter-
feron/ribavirin (PR) versus triple therapy regimens of boceprevir (BOC)/PR and 
telaprevir (TVR)/PR and PR dual therapy in treatment-naïve and treatment-expe-
rienced patients, chronically infected with hepatitis C virus (HCV) genotype 1, in 
Colombia. MethOds: A lifetime Markov model, applying a generally accepted 
structure, was used to estimate disease progression of HCV patients aged 50 years. 
Dosage regimens, including response-guided therapy were based on the approved 
labels for each product. Sustained viral response rates, were obtained from a mixed 
treatment comparison. Costs were estimated from health care system perspec-
tive and are expressed in local currency (COP). A review of the literature to obtain 
epidemiologic and resource utilization data was performed and when data were 
not available or validation was needed a Delphi panel with local experts was car-
ried out. Primary outcomes included discounted quality adjusted life years (QALYs) 
and costs. Deterministic and probabilistic sensitivity analyses were performed to 
assess uncertainty. Results: Treatment-naïve: In comparison with TVR/PR, BOC/
PR and PR, SMV/PR incurred 0.133, 0.171 and 0.858 additional QALYs, respectively. 
SMV/PR is dominant compared to BOC/PR and TVR/PR as more total QALYs are 
gained and less costs accrued. The cost-effectiveness ratio of SMV/PR vs. PR is esti-
mated at COP 22,984,021/QALY. Treatment experienced: In comparison with TVR/
PR, BOC/PR and PR, SMV/PR increased QALYs by 0.043, 0.133 and 1.064, respectively. 
SMV/PR is dominant compared to BOC/PR and TVR/PR as more total QALYs are 
gained and less costs accrued. The cost-effectiveness ratio of SMV/PR vs. PR is esti-
mated at COP 22,437,019/QALY. These results were robust in the sensitivity analy-
ses. cOnclusiOns: SMV/PR dominated TVR/PR and BOC/PR, and is a cost-effective 
treatment option against WHO 3x GDP criteria in comparison to PR alone for treat-
ment-naïve and treatment-experienced genotype 1 HCV patients in Colombia.
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Objectives: To assess the cost-effectiveness of simeprevir plus sofosbuvir +/- riba-
virin (SMV/SOF) versus sofosbuvir plus peginterferon/ribavirin (SOF/PR) and SOF/R 
regimens in treatment-naïve (METAVIR F3-F4) and prior-null-responder patients 
(F0-F4) infected with genotype 1 HCV in the Dominican Republic (DR). MethOds: 
A Markov model, based on existing cost-effectiveness analyses, was applied to esti-
mate disease progression of a cohort of genotype 1 HCV patients aged 47.8 years 
over a life time horizon. Sustained viral response (SVR) rates were obtained from 
the COSMOS study for SMV/SOF, from NEUTRINO for SOF/PR and from SPARE and 
QUANTUM for SOF/R. SVR rates for SOF/R and SOF/PR in null responder patients 
were conservatively assumed equal to treatment-naïve patients. Patient baseline 
characteristics, mortality, discount rates and unit costs were obtained from local 
sources. HCV progression rates and health related quality of life estimates were 
based on literature and HCV cost-effectiveness models. Various sensitivity and 
scenario analyses were conducted to assess uncertainty around the estimated dis-
counted quality adjusted life years (QALYs) and costs. Results: In the treatment-
naïve patient population, SMV/SOF accrued 0.59 more QALYs and incurred $330,982 
less costs per patient compared to SOF/R, resulting in SMV/SOF as the dominant 
treatment option. Compared to SOF/PR, SMV/SOF accrued 0.08 additional QALYs 
and $52,319 additional costs resulting in a cost-effectiveness ratio of $626,676 and 
was cost-effective against WHO 3GDP criteria. In the prior-null-responder popula-
tion, SMV/SOF dominated both comparators. Multivariate probabilistic sensitivity 
analyses showed that at a willingness-to-pay of $1,000,000, the probability of SMV/
SOF being cost-effective was estimated at 62% and 92% in the treatment-naïve and 
prior null responder population, respectively. cOnclusiOns: SMV/SOF provides 
higher efficacy compared to its competitors, especially for patients that are more 
difficult to treat (prior null responders). Compared to SOF/R and SOF/PR, SMV/SOF 
represents a cost-effective treatment option to treat genotype 1 HCV patients in DM.
INfECtIoN – Patient-reported outcomes & Patient Preference studies
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ObjetivOs: O protocolo para HIV/AIDS do Ministério da Saúde brasileiro garante 
acesso universal ao tratamento para as pessoas infectadas por esse vírus (BRASIL, 
2013). Os esquemas iniciais, preferencialmente recomendados, permanecem con-
stituídos por dois inibidores de Transcriptase reversa análogo de nucleosídeos 
(zidovudina+lamivudina) e um inibidor de transcriptase reversa não-análogo de 
nucleosídeos (efavirenz). Neste sentido, este trabalho, buscou determinar a adesão 
dos pacientes à primeira linha antirretroviral dessa tratativa. MétOdOs: Estudo 
longitudinal com 100 pacientes em Acompanhamento Farmacoterapêutico (AFT), 
utilizando o Método Dáder, atendidos em um Centro de Especialidades Médicas em 
Fortaleza-CE, no período de novembro/2008 a agosto/2012. Os dados foram anali-
sados em SPSS. Estudo aprovado pelo Comitê de Ética – Universidade Federal do 
Ceará (Protocolo Nº 191/08). ResultAdOs: Durante o AFT obteve-se média de 1,41 
esquemas/paciente, com uma mediana de 1,00; desvio padrão de 0,79 e máximo 
de 05 mudanças de esquemas de antirretrovirais. Na primeira linha, foram prescri-
tos 15 diferentes tipos de esquemas antirretrovirais. A adesão global ao protocolo 
governamental foi de 79%, sendo de 44%(44/100) a adesão ao padrão: (zidovudina 
+ lamivudina) + efavirenz, seguido do esquema alternativo envolvendo os inibi-
dores de protease lopinavir/ritonavir agregado aos inibidores nucleosídeos da 
transcriptase reversa zidovudina/lamivudina, em 25% (25/100) do total na primeira 
escolha. Observou-se que a lamivudina esteve presente na totalidade das escolhas 
en el número de casos de dengue reportados en Colombia. ResultAdOs: Al utilizar 
como referencia el criterio de la OMS para evaluar intervenciones en salud, incluy-
endo en el análisis el efecto indirecto de la vacunación y ajustando el número de 
casos de dengue reportados por el subregistro, se identifica que si la vacunación 
inicia en un periodo epidémico —desde la perspectiva del tercer pagador— el precio 
máximo por dosis para que la intervención sea costo-efectiva es US$ 65,61 si la 
vacuna es aplicada a la población en riesgo de nueve años; US$ 66,65 si se aplica en la 
población entre los nueve y diecisiete años; y US$ 33,37 vacunando a la población de 
nueve o más años. cOnclusiOnes: Estos resultados permiten identificar el precio 
máximo para que la intervención sea costo-efectiva considerando niveles de protec-
ción indirecta de la vacunación sobre los no-vacunados y considerando el ajuste 
por el subregistro en el número de casos reportados. Estos resultados representan 
la primera ocasión en que la vacuna contra el dengue de Sanofi Pasteur es evaluada 
a través de los resultados de eficacia obtenidos en su fase III en América Latina.
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Objectives: To assess the cost-effectiveness and cost-utility of simeprevir (SMV) 
plus peginterferon/ribavirin (PR) versus boceprevir (BOC)/PR in treatment-naïve 
patients [METAVIR F0-F3], versus PR in treatment-naïve [F0-F3 and F4] and treat-
ment-experienced patients in partial and null responders [F0-F4], and versus 
“no treatment” in treatment-experienced patients [F0-F4], chronically infected 
with hepatitis C virus (HCV) genotype 1, in Mexico. MethOds: A lifetime Markov 
model, was used to estimate disease progression for treatment-naïve and treat-
ment-experienced patients aged 47.8 years. Dosage regimens, including response-
guided therapy and futility stopping rules, were based on Mexican HCV treatment 
guidelines. Sustained viral response rates were obtained from relevant phase II/
III clinical trials. Patient baseline characteristics, mortality, discount rates and 
unit costs were obtained from local sources and an advisory board. HCV pro-
gression rates and health related quality of life estimates were based on pub-
lished literature and HCV cost-effectiveness models. Sensitivity analyses were 
conducted to estimate discounted quality adjusted life years (QALYs) and costs 
(in Mexican pesos). Results: In the treatment-naïve, F0-F3 population, SMV/PR 
was the dominant alternative, accruing more QALYs and less costs per patient 
compared to BOC/PR and PR alone (11.25 vs 11.08 and 10.67; $348,355 vs $455,709 
and $368,416, respectively). Likewise, SMV/PR was the dominant treatment option 
when compared with PR alone in the treatment-naïve, F4 population (7.43 vs 
6.85 QALYs; $668,475 vs $731,854, respectively) and treatment-experienced (9.27 
vs 8.42; $559,697 vs $609,751, respectively). Compared to “no treatment”, more 
costs and more QALYs were accumulated resulting in an incremental cost-utility 
ratio of $43,116 in the treatment-experienced population. Multivariate proba-
bilistic sensitivity analyses showed that at a willingness-to-pay threshold of 
$100,000, the probability that SMV/PR is cost-effective was > 80% for all treat-
ment groups. cOnclusiOns: SMV/PR appears a cost-effective treatment option 
in genotype 1 HCV patients compared to other regimens currently available in 
Mexico, regardless of treatment experience and fibrosis.
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Objectives: The prevention, diagnosis and treatment of chronic hepatitis C inte-
grates health policies in Brazil and worldwide. This disease affect many people, 
features high cost treatment and cause severe outcomes and disability, increasing 
social cost. We performed a cost-effectiveness analysis under the perspective of 
SUS, with the following strategies: treatment and retreatment with dual therapy, 
treatment with dual therapy and retreatment with triple therapy and treatment 
with triple therapy. MethOds: A Markov model was developed with a hypotheti-
cal cohort of 1000 adults, over 40 years, of both sexes, with confirmed diagnosis for 
chronic hepatitis C, monoinfected by HCV genotype 1 and absence of comorbidities.
The simulation started with all individuals carrying the milder form of the disease, 
considered F0 or F1, according to Metavir histological classification. Results: 
The results demonstrate the dual/triple therapy and triple therapy are below the 
acceptable threshold for embedding technology proposed by the WHO. Both are 
cost-effective. ICER of dual/triple therapy compared with base line was 7186.3 (R$/
QALY) and the triple therapy compared with dual/triple therapy was 59053.8 (R$/
QALY). However, the incremental cost of triple therapy compared to dual/triple 
therapy was 31029 and incremental effectiveness was 0.52. Triple therapy, despite 
having a little more effectiveness than the dual/triple therapy, showed much high-
ercost. cOnclusiOns: Thus, as would be consistent adopt one or the other for use 
in the SUS, since this system has limited resources, is better indicate the realization 
a budget impact analysis to have one more data information to support the decision 
to continue adopting the Brazilian guideline existing or suggest making another one.
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74% employed. In general, the HRQOL behavior was: Baseline: 75 [63-90], 1st: 82 
[70-88], 2nd: 83 [70-95]. When stratifying in terms of dimensions: Psychological: 
Baseline: 78 [63-85], 1st: 81 [70-86], 2nd: 81 [78-96]. Environmental: Baseline: 76 
[64-82], 1st: 82 [68-88], 2nd: 82 [76-95]. Physical health: Baseline: 81 [62-86], 1st: 81 
[70-81], 2nd: 81 [70-86]. Relationships: Baseline: 69 [57-80], 1st: 72 [57-80], 2nd: 76 
[57-100]. cOnclusiOns: the most affected dimension measured by the WHOQOL 
at the beginning of antiretroviral therapy was “Relationships”. The Environmental 
and Psychological dimensions experienced greater improvement according to time.
INfECtIoN – health Care use & Policy studies
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bENEfíCIos mAtErIAIs Como INCENtIvo PArA rEdução dE AbANdoNo dE 
trAtAmENto dE tubErCulosE Em PEssoAs vIvENdo Em sItuAção dE ruA: 
rEvIsão dE ANálIsEs ECoNômICAs
Elias FT1, Rodrigues D1, Esteves AC1, Silva E2
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ObjetivOs: Identificar opções de intervenções custo efetivas para incentivar 
redução de abandono da população em situação de rua a tratamentos de tubercu-
lose pulmonar. No Brasil foram notificados 73 833 casos novos na população geral 
em 2011. Estudos realizados em capitais relataram incidência de TB na população 
em situação de rua entre 1.576 e 2.750/100mil hab. Uma das populações prioritárias 
é aquela vivendo em situação de rua, devido a maior vulnerabilidade e risco e pelo 
alto percentual de abandono. MétOdOs: busca estruturada nas bases de dados, 
PubMed, BVS, CRD, Scopus,Science Direct e Web of Science. Foram considerados 
três critérios de inclusão: avaliação econômica, intervenções para tuberculose e 
população em situação de rua. ResultAdOs: sete estudos de 93 atenderam os 
critérios de inclusão. Desses, apenas dois abordaram formas de apoio para aumento 
da adesão ao tratamento pelos pacientes. TULSKY et al (2003) utilizaram dois tipos 
de incentivos para tratamento diretamente observado (TDO), um em dinheiro e 
outro em oferta de alimentação ou vale transporte. Ambos foram considerados 
viáveis economicamente para o aumento da adesão ao tratamento na PSR, com 
taxa de adesão de 86%. PHILIP et al (1999) analisaram o programa de alojamentos 
com alimentação e cuidados higiênicos e TDO. O custo diário de permanência no 
programa foi onze vezes mais barata que o custo diário de uma internação hos-
pitalar, o que geraria uma economia de mais de US$ 27 mil por paciente em 20 
meses. cOnclusões: Os dois estudos encontrados permitiram identificar duas 
opções de intervenções cost saving envolvendo oferta de benefícios materiais no 
contexto do País que desenvolveu a estratégia. As análises detalhadas dessas opções 
servirão para compor uma síntese de evidencias para políticas de saúde, destinadas 
a identificar opções viáveis para redução de abandono a tratamentos em populações 
altamente vulneráveis como aquelas vivendo em situação de rua.
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Costos dE mEdICAmENtos EN El mArCo dE uN ProGrAmA PrEsuPuEstAl 
PArA El vIh/sIdA EN PErú, 2012-2014
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ObjectivOs: Estimapgr el costo de medicamentos para la intervención de aten-
ción integral de personas diagnosticadas con VIH/SIDA, para reducir la morbimor-
talidad por VIH/SIDA en el Perú, 2011-2014. MetOdOlOgíAs: Se desarrolló bajo la 
metodología de uso de recursos médicos, en relación a medicamentos. Se tomó en 
consideración la asignación presupuestal en la intervención de atención integral 
de personas diagnosticadas con VIH/SIDA, en el marco del programa presupuestal. 
Se contrastó el uso de recursos médicos en medicamentos versus la cantidad de 
medicamentos antiretrovirales distribuidos a nivel nacional (Efavirenz 600mg, 
tableta) tomados del reporte de la Dirección de Abastecimientos de Recursos 
Estratégicos (DARES) del MINSA y los casos notificados de SIDA por año a nivel 
nacional tomados de la Dirección General de Epidemiología (DGE) del MINSA, 2012-
2014. ResultAdOs: El uso de recursos médicos en medicamentos se incrementó 
en el periodo 2012-2014 en 52% de $9.7 millones a $14.5 millones. Para el mismo 
periodo, la cantidad de antiretrovirales distribuidos (Efavirenz 600mg, tableta) se 
incrementó en 85% de 407,780 tabletas a 752,565 tabletas y los casos notificados de 
SIDA disminuyeron 13% de 1109 casos a 968 casos. cOnclusiOnes: La asignación 
presupuestal en medicamentos se ha incrementado, la cantidad de antiretroviral 
distribuido también se ha incrementado y los casos de SIDA han disminuido en el 
periodo 2012-2014.
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Objectives: Estimate the financpgial impact of current prescription practices for 
first time enrollees (FTE) financed by SP and calculate potential savings if physicians 
were adhered to the official guidelines. MethOds: Data for FTE about prescriptions, 
CD4, Viral Load and public purchase ART prices were obtained from CENSIDA for 
period January 2012 to Jun 2014. Information was analyzed to identify ART pre-
scriptions according to official guidelines. Average annual cost (AAC) of ART per 
enrollee was estimated under two scenarios of prescription: a) observed in practice; 
b) according to official guidelines. With the AAC of ART we estimated the potential 
savings that would be generated for SP. Results: Around 60% of ART observed pre-
scriptions for FTE adhered to official guidelines. AAC of current prescription for 9,500 
FTE amounts to US$34.1 million equivalent to 23% of financial resources available 
for high cost treatments in SP. If physicians would had adhered to the official guide-
lines savings for US$5.4 million that represents 16% of the total annual spending in 
FTE would had been generated in the period analyzed. On average FTE who initiate 
ART are maintained for 3.5 years with the initial scheme, thus savings that could 
terapêuticas iniciais prescritas e que os esquemas mais usados compreendiam o 
de três fármacos, correspondente a 86% (n= 86/100). cOnclusões: Os resultados 
apontaram uma adesão considerável, mas ainda há oportunidades de melhorias 
ao Protocolo Federal, com pacientes iniciando seus tratamentos com esquemas 
antirretrovirais diferentes do preconizado pelas Diretrizes do Ministério da Saúde 
brasileiro. No entanto, podem-se considerar algumas especificidades para estas 
escolhas e que podem requerer estudos mais aprofundados nesse cenário, com uma 
abordagem mais específica para uma melhor compreensão de suas causalidades.
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Objectives: The hepatitis C virus (HCV) is one of the most common blood-borne 
viral illnesses in Brazil and associated with various sequelae including cirrhosis 
and hepatocellular carcinoma. Treatment can be effective but also carries the risk 
of tolerability issues. The current study assessed the prevalence of tolerability issues 
among HCV patients and their association with health outcomes. MethOds: 
Data were derived from the 2011/2012 Brazil National Health and Wellness Survey 
(N= 24,000), an Internet-based health survey administered to a representative sam-
ple of the Brazilian adult population. HCV patients with treatment experience were 
categorized based on the presence or absence of tolerability issues. Patients with a 
diagnosis of anemia, a diagnosis of depression, or a positive screen for depression 
based on the Patient Health Questionnaire-9 (i.e., score of 5+) were considered to 
have tolerability issues. Patients with and without tolerability issues were com-
pared with respect to health outcomes (SF-36v2, Work Productivity and Activity 
Impairment questionnaire, and healthcare resource use) using regression mod-
eling. Results: N= 197 patients reported a diagnosis of HCV. Of these, N= 117 (53.9%) 
were currently using treatment (77.8% using either ribavirin and/or interferon-alfa) 
or had been treated in the past. 57.3% of patients (N= 67) experienced a tolerability 
issue. These patients had been diagnosed more recently compared with patients 
without a tolerability issue (13.4% vs. 6.0%, respectively, were diagnosed < 5 years 
ago; p< .05). No other demographic and healthy history differences were observed. 
The presence of tolerability issues was associated with worse health utilities (0.63 
vs. 0.75), a greater level of overall work impairment (48.3% vs. 9.67% work time 
missed or impaired), and more hospitalizations in the past 6 months (0.81 vs. 0.13) 
(all p< .05). cOnclusiOns: Anemia and depression are common tolerability issues 
among those with HCV in Brazil and are associated with significantly worse health 
outcomes. More tolerable treatments could have significant patient and societal 
benefits.
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Objectives: The aim of this study was to describe health-related quality of life 
(HRQoL) of HIV-infected patients attending to a university infectious diseases clinic 
in Venezuela. MethOds: A sample of 82 HIV-infected HIV patients attending an 
infectious diseases clinic at the Central University of Venezuela was interviewed 
by the investigator for 20 to 25 minutes. The interview was guided by a structured 
questionnaire that included questions on sociodemographic and clinical charac-
teristics, HRQoL, medication use, symptoms, and health behaviors. HRQoL was 
assessed using Spanish versions of EQ-5D descriptive system and EQ visual ana-
logue scale (EQ-VAS). HIV-symptoms were assessed using the Adult AIDS Clinical 
Trials Group (AACTG) symptom scale. Data concerning CD4-cell count and viral load 
was extracted from the medical records. All data analyses were performed using 
SSPS for Windows Version 19.0. Results: Of 82 participants, 50 (61%) were male 
and 32 (49%) were female. The mean age was 43.33 years (Range 18-73, SD= 10.378). 
Concerning the EQ-5D, none subject reported problems with self-care. Three sub-
jects (3.7%) reported some problems with mobility. Six subjects (7.3%) reported some 
problems with usual activity. Twenty nine subjects (35.4%) reported some problems 
with pain/discomfort and 28 subjects (34.1%) with anxiety/depression. Mean rate 
of own health on EQ-VAS was 84.77 (SD 15.927). The mean reported symptoms was 
38.84 (SD = 13.08; range 21-80). The mean CD4-cell count was 534.42 (SD = 264.02; 
range 75-1237). Fifty-two subjects (71.2%) had an undetectable viral load. Subjects 
were taking an average of 3.97 antiretroviral doses per day (SD = 1.81; range = 
1-8). cOnclusiOns: Study limitations include the sample size and the use of a 
convenient sample. Overall, this exploratory study demonstrates that quality of life 
among this group of HIV-infected patients in Venezuela was good.
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Objectives: assessment of health-related quality of life in a cohort of HIV-infected 
patients. MethOds: patients with diagnosis of HIV infection initiating antiretro-
viral therapy, receiving health education from a Pharmacist and a Doctor, belong-
ing to the Health promoting entity “SURA”, in the department of Antioquia (n= 70). 
Evaluation period: Between August 2014 and February 2015. Measurements: Baseline 
(diagnosis), second measurement (one month after), third measurement (three 
months after). Questionnaire used: The World Health Organization Quality of Life 
(WHOQOL)-BREF was used after previous approval of the World Health Organization 
and SURA’s Scientific Direction. The Statistical software “Rstudio Version 0.98.1103– 
©2009-2014 RStudio, Inc.” was used for that purpose. Results: average age: 31 
years [25-38], 92% men, 58% with higher education, 76% singles, 78% homosexuals, 
